Filana Therapeutics, Inc.
FLNARating Trend
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.22 | $-0.24 | — | — |
| Jul 29, 2026 | $-0.18 | $-0.23 | — | — |
| May 7, 2026 | $-0.21 | $-0.23 | — | — |
| Mar 12, 2026 | $-0.26 | $-0.30 | — | — |
| Nov 12, 2025 | $-0.22 | $-0.27 | — | — |
| Aug 14, 2025 | $-0.92 | — | — | — |
| May 8, 2025 | $-0.48 | — | — | — |
| Mar 3, 2025 | $-0.57 | $-0.58 | — | — |
News
Findings provide new insight into simufilam's effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the ATF4-associated cellular stress response Patient screening for planned Phase 2a study expected to begin by first quarter of 2027 AUSTIN, Texas, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently foc…
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company's management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York.
The U.S. Food and Drug Administration (FDA) on Tuesday removed a clinical hold on the investigational new drug application for Filana Therapeutics, Inc. (NASDAQ:FLNA).
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential investigators Ongoing collaboration with the TSC Alliance and the broader TSC community is intended to support patient engagement and study execution AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a b…
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug. 1
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.